Evaluating Improved Success Rate of Newer 6–9-month Treatment Regimen under Conditional Access Program in Patients with Drug-resistant Tuberculosis

Amitesh Gupta; Rupak Singla

doi:10.5005/jp-journals-11007-0053

SEARCH WITHIN CONTENT

Online First

Evaluating Improved Success Rate of Newer 6–9-month Treatment Regimen under Conditional Access Program in Patients with Drug-resistant Tuberculosis

Amitesh Gupta, Rupak Singla

Keywords : Multidrug-resistant tuberculosis, Research, Tuberculosis

Citation Information : Gupta A, Singla R. Evaluating Improved Success Rate of Newer 6–9-month Treatment Regimen under Conditional Access Program in Patients with Drug-resistant Tuberculosis. Indian J Chest Dis Allied Sci 2022; 64 (3):133-134.

DOI: 10.5005/jp-journals-11007-0053

License: CC BY-NC 4.0

Published Online: 08-12-2022

ARTICLE
REFERENCES

Abstract

HTML PDF Share

Behera D. To end tuberculosis, India must embrace innovation: Lessons from the ZeNix trial results. Indian J Chest Dis Allied Sci 2022; 64(2):63–64.
World Health Organization. Global tuberculosis report 2021. Available at: https://www.who.int/publications-detail-redirect/9789240037021 2022. Accessed on: 22 September, 2022.
Salhotra VS, Sachdeva KS, Kshirsagar N, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. Indian J Tuberc 2020;67(1):29–37. DOI: 10.1016/j.ijtb.2019.10.002.
World Health Organization. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis. Available at: https://www.who.int/publications/i/item/WHO-UCN-TB-2022-22022 2022.

PDF Share